Label Image (Lbl500906503)
This is a product label for a container of 60 capsules to be stored at 77 degrees Celsius.*
Pregabalin Capsule
Product Images NDC 50090-6503
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 50090-6503). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Equation (Pregabain Gault Equation)
This formula calculates the creatinine clearance rate (CLCr) based on the age of the patient in years and their weight in kilograms, as well as their serum creatinine level in mg/dL. For female patients, the final result is multiplied by 0.85.*
Fig-01 (Pregabalin Figure 01)
This text displays a chart with the percentage of patients who improved with different doses of Pregabalin compared to a placebo. It also shows the percentage of improvement in pain from baseline.*
Fig-02 (Pregabalin Figure 02)
The text represents a graph showing the percentage of patients who improved after taking Pregabalin compared to the placebo, and the percentage of improvement in pain from baseline. The graph shows that patients who took Pregabalin improved more than those who took the placebo. The X-axis shows the different comparison points, while the Y-axis shows the percentage of patients who improved and the percentage improvement in pain.*
Fig-03 (Pregabalin Figure 03)
This text shows the percent of patients that improved with different dosages of Pregabalin and a placebo. The improvement is based on pain reduction from a baseline. The percentage of patients improved can be seen in a graphical form.*
Fig-04 (Pregabalin Figure 04)
The text describes the level of improvement in pain experienced by patients taking Pregabalin at different dosages compared to a placebo. The percentage of patients who improved after taking the medication is shown on the left side of the chart, while the percentage improvement in pain from baseline is shown on the bottom axis.*
Fig-05 (Pregabalin Figure 05)
This document appears to be a chart or graph displaying the percent of patients improved based on different dosages of a medication called Pregabalin compared to a placebo. The chart also shows the percent improvement in pain from baseline at various levels, ranging from 10% to 100%.*
Fig-06 (Pregabalin Figure 06)
This is a table showing responder rates (%) and dosages for different studies. The studies are labeled E1 and E3. The table shows dosages of 50mg/day, 150mg/day, 300mg/day, and 600mg/day. The placebo rate is 100%. Some of the dosage percentages are statistically significant compared to placebo. There is no additional context available.*
Fig-07 (Pregabalin Figure 07)
This appears to be a graph or chart displaying data related to some type of medical or pharmaceutical study. The graph displays the doses of medication administered (in mg/day) on the x-axis, and on the y-axis are values measured in the study (the type of which is not indicated by this text). The graph shows several data points representing different doses of medication, and the p-values associated with those data points (shown as p<0.0001 and p=0.000) suggest that the medication reliably produced certain effects compared to a placebo control. The graph appears to have been generated by a software program capable of (optical character recognition).*
Fig-09 (Pregabalin Figure 09)
This text depicts a graph that shows the percent of patients improved with different doses of Pregabalin and placebo. The doses of Pregabalin are 600mg, 450mg, and 300mg daily. The vertical axis represents percent improvement, and the horizontal axis represents percent improvement in pain from baseline. There is no further information available.*
Fig-10 (Pregabalin Figure 10)
This appears to be a chart or graph representing the estimated percentage of subjects without LIR (unknown acronym) based on different levels of medication (Pregabalin versus Placebo) over a period of 180 days. The X-axis displays the number of days observed, while the Y-axis represents the estimated percentage of subjects without LIR. The percentage values range from 0 to 100.*
Fig-11 (Pregabalin Figure 11)
This is a chart indicating the percentage of subjects who showed improvement from baseline to week 12 on Pregabalin versus Placebo. The chart shows percentage values on the Y-axis and time intervals (in weeks) on the X-axis.*
Fig-12 (Pregabalin Figure 12)
Str (Pregabalin Structure)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
